NS5A inhibitors in the treatment of hepatitis C
Summary Hepatitis C virus infection is a major health problem worldwide and no vaccine has yet been developed against this virus. In addition, currently approved pharmacotherapies achieve suboptimal cure rates and have side effects that result in non-compliance and premature treatment discontinuatio...
Gespeichert in:
| Veröffentlicht in: | Journal of hepatology 2013-08, Vol.59 (2), p.375-382 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 382 |
|---|---|
| container_issue | 2 |
| container_start_page | 375 |
| container_title | Journal of hepatology |
| container_volume | 59 |
| creator | Pawlotsky, Jean-Michel |
| description | Summary Hepatitis C virus infection is a major health problem worldwide and no vaccine has yet been developed against this virus. In addition, currently approved pharmacotherapies achieve suboptimal cure rates and have side effects that result in non-compliance and premature treatment discontinuation. Significant research has been devoted to developing direct-acting antiviral agents that inhibit key viral functions. In particular, several novel drug candidates that inhibit the viral non-structural protein 5A (NS5A) have been demonstrated to possess high potency, pan-genotypic activity, and a high barrier to resistance. Clinical trials using combination therapies containing NS5A inhibitors have reported results that promise high cure rates and raise the possibility of developing interferon-free, all-oral regimens. |
| doi_str_mv | 10.1016/j.jhep.2013.03.030 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1411629958</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168827813002092</els_id><sourcerecordid>1411629958</sourcerecordid><originalsourceid>FETCH-LOGICAL-c554t-25cc0759beda15dcfe655b1e6f6bc81579f63d05b2659ab3cc15b2b90980ca953</originalsourceid><addsrcrecordid>eNp9kU1LxDAQhoMoun78AQ_So5euk7TJNiCCLH7Bogf1HNJ0yqZ22zVJhf33puzqwYMwMHN43neYdwg5pzClQMVVM22WuJ4yoNkUxoI9MqECIAWR030yiVCRFmxWHJFj7xuAiMj8kByxjIsZFPmEXD2_8tvEdktb2tA7H8ckLDEJDnVYYReSvk7iFh1ssD6Zn5KDWrcez3b9hLzf373NH9PFy8PT_HaRGs7zkDJuDMy4LLHSlFemRsF5SVHUojQF5TNZi6wCXjLBpS4zY2icSwmyAKMlz07I5dZ37frPAX1QK-sNtq3usB-8ojmlgknJi4iyLWpc773DWq2dXWm3URTUGJRq1BiUGoNSMBZE0cXOfyhXWP1KfpKJwPUWwHjll0WnvLHYGaysQxNU1dv__W_-yE1rO2t0-4Eb9E0_uC7mp6jyTIF6HV81fopmAAwky74B1TaMgw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1411629958</pqid></control><display><type>article</type><title>NS5A inhibitors in the treatment of hepatitis C</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Pawlotsky, Jean-Michel</creator><creatorcontrib>Pawlotsky, Jean-Michel</creatorcontrib><description>Summary Hepatitis C virus infection is a major health problem worldwide and no vaccine has yet been developed against this virus. In addition, currently approved pharmacotherapies achieve suboptimal cure rates and have side effects that result in non-compliance and premature treatment discontinuation. Significant research has been devoted to developing direct-acting antiviral agents that inhibit key viral functions. In particular, several novel drug candidates that inhibit the viral non-structural protein 5A (NS5A) have been demonstrated to possess high potency, pan-genotypic activity, and a high barrier to resistance. Clinical trials using combination therapies containing NS5A inhibitors have reported results that promise high cure rates and raise the possibility of developing interferon-free, all-oral regimens.</description><identifier>ISSN: 0168-8278</identifier><identifier>EISSN: 1600-0641</identifier><identifier>DOI: 10.1016/j.jhep.2013.03.030</identifier><identifier>PMID: 23567084</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Oral ; Anilides - therapeutic use ; Antiviral Agents - administration & dosage ; Antiviral Agents - therapeutic use ; Benzimidazoles - therapeutic use ; Carbamates - therapeutic use ; Clinical Trials as Topic ; Daclatasvir ; Drug Resistance, Viral - genetics ; Drug Therapy, Combination ; Fluorenes - therapeutic use ; Gastroenterology and Hepatology ; Hepacivirus - drug effects ; Hepacivirus - genetics ; Hepacivirus - physiology ; Hepatitis C virus ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - virology ; Humans ; Imidazoles - therapeutic use ; NS5A inhibitor ; Proline ; Pyrrolidines ; Resistance ; Valine - analogs & derivatives ; Viral Nonstructural Proteins - antagonists & inhibitors ; Viral Nonstructural Proteins - genetics ; Viral Nonstructural Proteins - physiology</subject><ispartof>Journal of hepatology, 2013-08, Vol.59 (2), p.375-382</ispartof><rights>European Association for the Study of the Liver</rights><rights>2013 European Association for the Study of the Liver</rights><rights>Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c554t-25cc0759beda15dcfe655b1e6f6bc81579f63d05b2659ab3cc15b2b90980ca953</citedby><cites>FETCH-LOGICAL-c554t-25cc0759beda15dcfe655b1e6f6bc81579f63d05b2659ab3cc15b2b90980ca953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168827813002092$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23567084$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pawlotsky, Jean-Michel</creatorcontrib><title>NS5A inhibitors in the treatment of hepatitis C</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>Summary Hepatitis C virus infection is a major health problem worldwide and no vaccine has yet been developed against this virus. In addition, currently approved pharmacotherapies achieve suboptimal cure rates and have side effects that result in non-compliance and premature treatment discontinuation. Significant research has been devoted to developing direct-acting antiviral agents that inhibit key viral functions. In particular, several novel drug candidates that inhibit the viral non-structural protein 5A (NS5A) have been demonstrated to possess high potency, pan-genotypic activity, and a high barrier to resistance. Clinical trials using combination therapies containing NS5A inhibitors have reported results that promise high cure rates and raise the possibility of developing interferon-free, all-oral regimens.</description><subject>Administration, Oral</subject><subject>Anilides - therapeutic use</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Benzimidazoles - therapeutic use</subject><subject>Carbamates - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Daclatasvir</subject><subject>Drug Resistance, Viral - genetics</subject><subject>Drug Therapy, Combination</subject><subject>Fluorenes - therapeutic use</subject><subject>Gastroenterology and Hepatology</subject><subject>Hepacivirus - drug effects</subject><subject>Hepacivirus - genetics</subject><subject>Hepacivirus - physiology</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - virology</subject><subject>Humans</subject><subject>Imidazoles - therapeutic use</subject><subject>NS5A inhibitor</subject><subject>Proline</subject><subject>Pyrrolidines</subject><subject>Resistance</subject><subject>Valine - analogs & derivatives</subject><subject>Viral Nonstructural Proteins - antagonists & inhibitors</subject><subject>Viral Nonstructural Proteins - genetics</subject><subject>Viral Nonstructural Proteins - physiology</subject><issn>0168-8278</issn><issn>1600-0641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1LxDAQhoMoun78AQ_So5euk7TJNiCCLH7Bogf1HNJ0yqZ22zVJhf33puzqwYMwMHN43neYdwg5pzClQMVVM22WuJ4yoNkUxoI9MqECIAWR030yiVCRFmxWHJFj7xuAiMj8kByxjIsZFPmEXD2_8tvEdktb2tA7H8ckLDEJDnVYYReSvk7iFh1ssD6Zn5KDWrcez3b9hLzf373NH9PFy8PT_HaRGs7zkDJuDMy4LLHSlFemRsF5SVHUojQF5TNZi6wCXjLBpS4zY2icSwmyAKMlz07I5dZ37frPAX1QK-sNtq3usB-8ojmlgknJi4iyLWpc773DWq2dXWm3URTUGJRq1BiUGoNSMBZE0cXOfyhXWP1KfpKJwPUWwHjll0WnvLHYGaysQxNU1dv__W_-yE1rO2t0-4Eb9E0_uC7mp6jyTIF6HV81fopmAAwky74B1TaMgw</recordid><startdate>20130801</startdate><enddate>20130801</enddate><creator>Pawlotsky, Jean-Michel</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130801</creationdate><title>NS5A inhibitors in the treatment of hepatitis C</title><author>Pawlotsky, Jean-Michel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c554t-25cc0759beda15dcfe655b1e6f6bc81579f63d05b2659ab3cc15b2b90980ca953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Administration, Oral</topic><topic>Anilides - therapeutic use</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Benzimidazoles - therapeutic use</topic><topic>Carbamates - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Daclatasvir</topic><topic>Drug Resistance, Viral - genetics</topic><topic>Drug Therapy, Combination</topic><topic>Fluorenes - therapeutic use</topic><topic>Gastroenterology and Hepatology</topic><topic>Hepacivirus - drug effects</topic><topic>Hepacivirus - genetics</topic><topic>Hepacivirus - physiology</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - virology</topic><topic>Humans</topic><topic>Imidazoles - therapeutic use</topic><topic>NS5A inhibitor</topic><topic>Proline</topic><topic>Pyrrolidines</topic><topic>Resistance</topic><topic>Valine - analogs & derivatives</topic><topic>Viral Nonstructural Proteins - antagonists & inhibitors</topic><topic>Viral Nonstructural Proteins - genetics</topic><topic>Viral Nonstructural Proteins - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pawlotsky, Jean-Michel</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pawlotsky, Jean-Michel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NS5A inhibitors in the treatment of hepatitis C</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2013-08-01</date><risdate>2013</risdate><volume>59</volume><issue>2</issue><spage>375</spage><epage>382</epage><pages>375-382</pages><issn>0168-8278</issn><eissn>1600-0641</eissn><abstract>Summary Hepatitis C virus infection is a major health problem worldwide and no vaccine has yet been developed against this virus. In addition, currently approved pharmacotherapies achieve suboptimal cure rates and have side effects that result in non-compliance and premature treatment discontinuation. Significant research has been devoted to developing direct-acting antiviral agents that inhibit key viral functions. In particular, several novel drug candidates that inhibit the viral non-structural protein 5A (NS5A) have been demonstrated to possess high potency, pan-genotypic activity, and a high barrier to resistance. Clinical trials using combination therapies containing NS5A inhibitors have reported results that promise high cure rates and raise the possibility of developing interferon-free, all-oral regimens.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>23567084</pmid><doi>10.1016/j.jhep.2013.03.030</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8278 |
| ispartof | Journal of hepatology, 2013-08, Vol.59 (2), p.375-382 |
| issn | 0168-8278 1600-0641 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1411629958 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Administration, Oral Anilides - therapeutic use Antiviral Agents - administration & dosage Antiviral Agents - therapeutic use Benzimidazoles - therapeutic use Carbamates - therapeutic use Clinical Trials as Topic Daclatasvir Drug Resistance, Viral - genetics Drug Therapy, Combination Fluorenes - therapeutic use Gastroenterology and Hepatology Hepacivirus - drug effects Hepacivirus - genetics Hepacivirus - physiology Hepatitis C virus Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Humans Imidazoles - therapeutic use NS5A inhibitor Proline Pyrrolidines Resistance Valine - analogs & derivatives Viral Nonstructural Proteins - antagonists & inhibitors Viral Nonstructural Proteins - genetics Viral Nonstructural Proteins - physiology |
| title | NS5A inhibitors in the treatment of hepatitis C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T16%3A25%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NS5A%20inhibitors%20in%20the%20treatment%20of%20hepatitis%20C&rft.jtitle=Journal%20of%20hepatology&rft.au=Pawlotsky,%20Jean-Michel&rft.date=2013-08-01&rft.volume=59&rft.issue=2&rft.spage=375&rft.epage=382&rft.pages=375-382&rft.issn=0168-8278&rft.eissn=1600-0641&rft_id=info:doi/10.1016/j.jhep.2013.03.030&rft_dat=%3Cproquest_cross%3E1411629958%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1411629958&rft_id=info:pmid/23567084&rft_els_id=S0168827813002092&rfr_iscdi=true |